Abivax S.A. (ABVX) has a negative trailing P/E of -21.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 98.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -4.68%, forward earnings yield 1.02%. PEG 0.65 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.3 | 0.52 | 1.34 | 599.02 | - |
| 2017 | -6.1 | 0.26 | 1.42 | 6,824.14 | - |
| 2018 | -4.7 | -0.13 | 2.13 | 4,091.34 | - |
| 2019 | -2.9 | -0.05 | 4.85 | 45,076.57 | - |
| 2020 | -2.6 | -0.59 | 5.43 | 1,542.27 | - |
| 2021 | -2.7 | -0.54 | 4.35 | 3,049.02 | - |
| 2022 | -2.4 | -0.16 | 20.59 | 32.29 | - |
| 2023 | -2.8 | -0.36 | 2.13 | 90.22 | - |
| 2024 | -2.5 | 0.14 | 10.98 | 41.30 | - |
| 2025 | -24.7 | -0.37 | 17.54 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.47 | $127K | $-14.31M | -11266.1% |
| 2017 | $-1.13 | $10K | $-11.22M | -112230% |
| 2018 | $-1.55 | $18K | $-15.82M | -87905.6% |
| 2019 | $-2.51 | $2K | $-30.63M | -1531700% |
| 2020 | $-2.62 | $63K | $-37.55M | -59604.8% |
| 2021 | $-2.75 | $37K | $-42.45M | -114735.1% |
| 2022 | $-3.18 | $4.58M | $-60.74M | -1325.3% |
| 2023 | $-3.43 | $4.62M | $-147.74M | -3197.1% |
| 2024 | $-2.80 | $10.79M | $-176.24M | -1633.1% |
| 2025 | $-4.65 | $0.00 | $-322.84M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.34 | $-3.71 – $-2.48 | $3.42M | $2.65M – $4.18M | 5 |
| 2027 | $-2.73 | $-3.53 – $-1.05 | $131.83M | $105.09M – $160.96M | 4 |
| 2028 | $1.28 | $0.68 – $1.88 | $661.25M | $526.65M – $807.38M | 2 |
| 2029 | $7.30 | $5.37 – $9.40 | $1.34B | $1.07B – $1.64B | 1 |
| 2030 | $8.08 | $5.94 – $10.40 | $1.74B | $1.39B – $2.13B | 1 |
